IVD Market in North America expected to Grow faster with key winning strategies

The North America IVD Market is accounted for $20,886 million in 2016, and is estimated to reach $27.820 million by 2023, growing at a CAGR of 4.1% during the analysis period 2017-2023.

Major companies operating in this market adopt product launch as their key development strategy. Companies profiled in this market include, Thermo Fisher Scientific Inc., Alere Inc., Biomerieux, Danaher Corporation, F. Hoffmann-La Roche AG, Becton Dickinson and Company, Bio-Rad Laboratories, Bayer AG, Sysmex Corporation, and Johnson & Johnson among others.

Get Sample PDF Brochure of North America IVD Market Study at : 

https://www.alliedmarketresearch.com/request-sample/4347

IVD products are those agents, instruments, and systems utilized to examine samples such as blood, urine, stool, tissues, and other body fluids. These samples are derived from the human body to detect diseases, conditions, and infections. The tests can be performed in standalone laboratory, and hospital-based laboratory. IVD utilizes several techniques, such as polymerase chain reaction, microarray techniques, sequencing technology and mass spectrometry for test sample preparation to detect diseases.

Based on product type, the market is categorized into reagents, instruments, and software & services. The reagent segment accounted for the highest market share in 2016, and the software and services is expected to grow at the highest growth rate during the forecast period. The growth of the reagent market is attributed to the recent introduction of new novel reagents and wide availability of effective and cost-efficient reagents. On the basis of technique, the immunodiagnostics segment captured the highest market share in 2016, due to the increase in demand of personalized medicines.

On the basis of application, infectious diseases segment captured the highest market share in 2016, because of the increase in prevalence of infectious diseases and rise in healthcare awareness among the population. Based on end users, the standalone laboratory segment captured the highest market share in 2016, primarily due to non-availability of complex tests in hospitals and commercial clinics.